【摘要】 目的 评估鳞状细胞癌抗原(SCCA)及人乳头瘤病毒(HPV)联合检测在宫颈癌诊断中的临床应用价值。方法 回顾性分析102例疑似宫颈癌患者的临床资料。对所有患者进行HPV DNA检测、SCCA血清水平检测和宫颈液基薄层细胞学(TCT)检测。采用ROC曲线分析评估诊断效能，并进行统计学分析。结果 SCCA和HPV联合检测在宫颈癌患者中阳性率(98.6%)显著高于单独检测。联合检测的曲线下面积(AUC=0.97)优于SCCA(AUC=0.85)或HPV(AUC=0.91)单独检测。SCCA水平随宫颈癌病理分级升高而显著增高(P<0.01)。SCCA与HPV检测结果呈显著正相关(γ=0.344,P<0.01)。结论 SCCA和HPV联合检测可显著提高宫颈癌诊断的敏感性和特异性，为宫颈癌的早期诊断和风险评估提供了新的临床工具。更多还原

【Abstract】 Objective To evaluate the clinical application value of combined detection of squamous cell carcinoma antigen(SCCA)and human papillomavirus(HPV)in the diagnosis of cervical cancer.Methods A retrospective analysis was conducted on the clinical data of 102 suspected cervical cancer patients.Perform HPV DNA testing, SCCA serum level testing, and cervical liquid based thin-layer cytology(TCT)testing on all patients.Use ROC curve analysis to evaluate diagnostic efficacy and conduct statistical analysis.Results The positive rate of SCCA and HPV combined testing in cervical cancer patients(98.6%)was significantly higher than that of testing alone.The area under the curve for joint detection(AUC=0.97)is superior to SCCA(AUC=0.85)or HPV(AUC=0.91)detection alone.The level of SCCA significantly increased with the pathological grading of cervical cancer(P<0.01).The results of SCCA and HPV testing showed a significant positive correlation(γ=0.344,P<0.01).Conclusion The combined detection of SCCA and HPV can significantly improve the sensitivity and specificity of cervical cancer diagnosis, providing a new clinical tool for early diagnosis and risk assessment of cervical cancer.更多还原